...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Lenalidomide: the emerging role of a novel targeted agent in malignancies.
【24h】

Lenalidomide: the emerging role of a novel targeted agent in malignancies.

机译：来那度胺：新型靶向药物在恶性肿瘤中的新兴作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lenalidomide is an immunomodulatory drug that was developed by modification of the first-generation immunomodulatory drug thalidomide in a drug discovery program. Lenalidomide more potently regulates cellular immune and cytokine responses, while lacking the side-effect profile of thalidomide. The promising activity seen in multiple myeloma and myelodysplastic syndrome has led to its approval by the U.S. Food and Drug Administration in these conditions. The clinical results that we have seen so far, which demonstrate significant efficacy with a tolerable toxicity profile, provide a strong basis for the use of lenalidomide in other malignancies. Combination therapy with lenalidomide could enhance this agent's antineoplastic role; this is likely the position it will occupy in the armamentarium against cancer.
机译：来那度胺是一种通过在药物发现程序中对第一代免疫调节药物沙利度胺进行修饰而开发的免疫调节药物。来那度胺更有效地调节细胞免疫和细胞因子反应，同时缺乏沙利度胺的副作用。在多发性骨髓瘤和骨髓增生异常综合症中看到的有希望的活动已导致其在这些情况下获得美国食品药品监督管理局的批准。到目前为止，我们已经看到的临床结果显示了显着的疗效和可耐受的毒性，为来那度胺在其他恶性肿瘤中的使用提供了坚实的基础。来那度胺联合治疗可增强该药的抗肿瘤作用;这很可能会在抗癌武器库中占据一席之地。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号